Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases. Allenaâs second product candidate, ALLN-346, is in preclinical development for patients with hyperuricemia and moderate to severe CKD. Hyperuricemia, or elevated levels of uric acid in the blood, is commonly associated with gout as well as kidney stones and kidney disorders. Source
No articles found.
Silk Road Medical is a medical device company focused on reducing the risk of stro...
Silk Road Medical is a medical device company f...
Tactile Medical is a leader in developing and marketing at-home therapy devices th...
Tactile Medical is a leader in developing and m...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing...
scPharmaceuticals is a clinical-stage pharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.